Sources: NTRB Website. NTRB Presentation.
-----
As mentioned above, NTRB has several potential catalysts that could create breakout buzz. Here's a few to consider now:
#1. NTRB Potential Catalyst - A Low Float Could Create An Exceptionally Volatile Environment (Daily).
According to info from the Yahoo Finance website, NTRB has a pretty low float.
The website reports this profile to have roughly 5.05Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
Could positive company news early in 2025 provide a breakout spark?
-----
#2. NTRB Potential Catalyst - Company's Subsidiary Sees Revenue Pop Off In Q3, Up Approx. 50%!
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fent-a-nyl in 2025
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its fi-nan-cial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fent-a-nyl, with an NDA submission targeted for first half of 2025.
Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record third quarter reporting revenue of $645k+ USD, up 50.94% YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS.
Progress continues on the development of AVERSA Fent-a-nyl, with the Company maintaining its goal of submitting an NDA to the FDA in the first half of 2025. Nutriband recently updated shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before submission.
If approved, AVERSA Fent-a-nyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fent-a-nyl is estimated to have the potential to reach peak annual sales of $80-$200Mn, according to a market analysis report from Health Advances.
AVERSA Buprenorphine, which is the company's second application for AVERSA, is projected to reach peak annual sales of up to $130Mn.
...
Read the full article here.
-----
#3. NTRB Potential Catalyst - Strong Patent News Could Put NTRB In A Strengthened Position To Defend And Commercialize AVERSA™.
A handful of positive patent-related press releases have popped up in the last few months. Take a look:
12/27/24 - Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
11/27/24 - Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
10/31/24 - Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
These developments strengthen NTRB's ability to defend and commercialize AVERSA™ globally, setting the stage for Nutriband to become the leader in abuse-deterrent technology.
-----
#4. NTRB Potential Catalyst - Don't Look Past NTRB's Explosive Chart History As Multiple Surges Have Appeared Over The Past Year.
Take a look at NTRB's 1-year chart:
